Suwanee, United States
Femasys Inc., founded in 2004, is a pioneering biomedical company dedicated to revolutionizing women’s healthcare globally. This company is strategically embedded in multiple industries, including biotechnology, health care, and women's health, aiming to address critical gaps in treatment and care.
Central to Femasys’s innovation are two key product candidates: FemBloc®, a revolutionary non-surgical permanent birth control solution, and FemaSeed™, a breakthrough in infertility treatment through directed sperm delivery. Alongside these innovations, the FemVue® product offers a unique ultrasound-based solution for fallopian tube assessment and is their primary commercial focus in the United States.
In its latest financing development, Femasys secured a $6.85 million post-IPO debt investment from PharmaCyte Biotech on 15 November 2023, bolstering efforts to expand their market presence and develop their tissue sampling technology for in-office use.
